Even If Bills to Hasten Drug Approvals Pass, Investments May Remain Dry Longer Than Stakeholders Claim

Congress appears poised this year to deliver on years of lobbying by industry to speed up reviews of new drugs and cut regulatory red tape. That helping hand alone, however, isn’t likely enough to draw investors, still shell-shocked by the recession, back into funding new biopharma startups and early-stage companies.
Genetic Engineering & Biotechnology News